Gapping down:
Following news: TSRO -7.16% (announces successful achievement of Primary Endpoint in each of two Phase 3 trials of Rolapitant for the prevention of Chemotherapy-induced nausea & vomiting ), TSEM -5.69% (still checking), NBG -3.94% (still checking for anything specific), TIF -2.89% (ordered to pay Swatch ~$449.5 mln in damages from Dutch arbitration; TIF sees $2.30-2.35 (~63% impact) to FY14 EPS)
Analyst comments: MU -2.21% (downgraded to Underperform from Neutral at BofA/Merrill)
Analyst comments: MU -2.21% (downgraded to Underperform from Neutral at BofA/Merrill)